Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 807

1.

The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.

Juusola JL, Brandeau ML, Owens DK, Bendavid E.

Ann Intern Med. 2012 Apr 17;156(8):541-50. doi: 10.7326/0003-4819-156-8-201204170-00001.

PMID:
22508731
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Long EF, Brandeau ML, Owens DK.

Ann Intern Med. 2010 Dec 21;153(12):778-89. doi: 10.7326/0003-4819-153-12-201012210-00004.

PMID:
21173412
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis.

Long EF.

PLoS One. 2011;6(11):e27625. doi: 10.1371/journal.pone.0027625. Epub 2011 Nov 16.

PMID:
22110698
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA.

Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E.

AIDS. 2011 Sep 10;25(14):1779-87. doi: 10.1097/QAD.0b013e328349f067.

PMID:
21716076
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.

Long EF, Stavert RR.

J Gen Intern Med. 2013 Oct;28(10):1294-301. doi: 10.1007/s11606-013-2417-1. Epub 2013 Apr 16.

PMID:
23588668
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.

Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G.

Health Technol Assess. 2010 Nov;14(53):iii-iv, ix-x, 1-101. doi: 10.3310/hta14530. Review.

PMID:
21083999
[PubMed - indexed for MEDLINE]
Free Article
7.

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP.

Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.

PMID:
19193111
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA.

Ann Intern Med. 2006 Dec 5;145(11):797-806.

PMID:
17146064
[PubMed - indexed for MEDLINE]
9.

The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.

Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB.

PLoS Med. 2012;9(10):e1001323. doi: 10.1371/journal.pmed.1001323. Epub 2012 Oct 9.

PMID:
23055836
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Review.

PMID:
18646068
[PubMed - indexed for MEDLINE]
11.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
[PubMed - indexed for MEDLINE]
12.

Sexual partnerships and considerations for HIV antiretroviral pre-exposure prophylaxis utilization among high-risk substance using men who have sex with men.

Mimiaga MJ, Closson EF, Kothary V, Mitty JA.

Arch Sex Behav. 2014 Jan;43(1):99-106. doi: 10.1007/s10508-013-0208-8.

PMID:
24243002
[PubMed - indexed for MEDLINE]
13.

The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Long EF, Owens DK.

Vaccine. 2011 Aug 18;29(36):6113-24. doi: 10.1016/j.vaccine.2011.04.013. Epub 2011 Apr 19.

PMID:
21510996
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
[PubMed - indexed for MEDLINE]
15.

Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.

Alistar SS, Owens DK, Brandeau ML.

PLoS Med. 2011 Mar;8(3):e1000423. doi: 10.1371/journal.pmed.1000423. Epub 2011 Mar 1.

PMID:
21390264
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
[PubMed - indexed for MEDLINE]
17.

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Freedberg KA, Walensky RP.

N Engl J Med. 2005 Feb 10;352(6):586-95.

PMID:
15703423
[PubMed - indexed for MEDLINE]
Free Article
18.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
[PubMed - indexed for MEDLINE]
19.

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9.

PMID:
22874836
[PubMed - indexed for MEDLINE]
Free Article
20.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

PMID:
16904046
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk